Erin K. Crane, MD, MPH
Advertisement
Articles by Erin K. Crane, MD, MPH
Erin K. Crane, MD, MPH, discusses the impact of the phase 3 PRIMA trial on second-line maintenance approaches in ovarian cancer.
Erin K. Crane, MD, MPH, discusses findings from 3 trials demonstrating the benefits of PARP inhibitor maintenance in patients with ovarian cancer.
OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.
Erin K. Crane, MD, MPH, discusses the benefit of maintenance PARP inhibitors in ovarian cancer.
Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the toxicity profile of combination regimens for patients with ovarian cancer.
Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses combinations with PARP inhibitors in ovarian cancer.
Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the impact of PARP inhibitors for patients with ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Crane on Combinations With PARP Inhibitors in Ovarian CancerFebruary 16th 2018
Dr. Crane on the Impact of PARP Inhibitors in Ovarian CancerFebruary 8th 2018
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
5